Yan M, Ouyang Q, Sun T, Niu L, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol 2022 Jan 24. pii: S1470-2045(21)00716.
PMID: 35085506